- Home
- LYB vs BIIB Comparison
LYB vs BIIB Comparison
Compare LYB & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYB
- BIIB
- Stock Information
- Founded
- LYB 1955
- BIIB 1978
- Country
- LYB United States
- BIIB United States
- Employees
- LYB N/A
- BIIB N/A
- Industry
- LYB Major Chemicals
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- LYB Industrials
- BIIB Health Care
- Exchange
- LYB Nasdaq
- BIIB Nasdaq
- Market Cap
- LYB 20.3B
- BIIB 18.7B
- IPO Year
- LYB N/A
- BIIB 1991
- Fundamental
- Price
- LYB $54.14
- BIIB $141.04
- Analyst Decision
- LYB Hold
- BIIB Buy
- Analyst Count
- LYB 14
- BIIB 27
- Target Price
- LYB $65.71
- BIIB $188.09
- AVG Volume (30 Days)
- LYB 4.2M
- BIIB 1.4M
- Earning Date
- LYB 10-31-2025
- BIIB 10-29-2025
- Dividend Yield
- LYB 10.03%
- BIIB N/A
- EPS Growth
- LYB N/A
- BIIB 31.67
- EPS
- LYB 0.77
- BIIB 10.45
- Revenue
- LYB $38,655,000,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- LYB N/A
- BIIB $2.00
- Revenue Next Year
- LYB $0.35
- BIIB N/A
- P/E Ratio
- LYB $70.80
- BIIB $13.52
- Revenue Growth
- LYB 2.98
- BIIB 3.36
- 52 Week Low
- LYB $47.55
- BIIB $110.04
- 52 Week High
- LYB $97.60
- BIIB $204.18
- Technical
- Relative Strength Index (RSI)
- LYB 45.24
- BIIB 60.59
- Support Level
- LYB $52.93
- BIIB $137.14
- Resistance Level
- LYB $56.30
- BIIB $144.20
- Average True Range (ATR)
- LYB 1.66
- BIIB 3.89
- MACD
- LYB 0.13
- BIIB 0.32
- Stochastic Oscillator
- LYB 24.57
- BIIB 70.33
About LYB LyondellBasell Industries NV (Netherlands)
LyondellBasell is a petrochemical producer with operations in the United States, Europe, and Asia. The company is the world's largest producer of polypropylene and also a major producer of polyethylene and propylene oxide. Its chemicals are used in various consumer and industrial end products. Well over half of LyondellBasell's production comes from its North American operations.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.